Clinical trial
A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects (The Patiromer JADE Study)
NCT05136664 is registered in ClinicalTrials.gov with Vifor Fresenius Medical Care Renal Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects (The Patiromer JADE Study)
- Lead sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 10, 2022
- Completion date
- November 18, 2025
- Enrollment
- 262 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.